tiprankstipranks
Bristol-Myers receives EC approval of Reblozyl
The Fly

Bristol-Myers receives EC approval of Reblozyl

Bristol Myers Squibb announced that the European Commission has granted full Marketing Authorization for Reblozyl, a first-in-class therapeutic option, for treatment in adult patients of anemia associated with non-transfusion-dependent beta thalassemia. Reblozyl is currently approved in the European Union, United States and Canada to address anemia associated with transfusion-dependent beta thalassemia and transfusion-dependent lower-risk myelodysplastic syndromes. The centralized Marketing Authorization approves use of Reblozyl in all EU member states, as well as Norway, Iceland and Liechtenstein.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on BMY:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles